[A single-center clinical study of 22 patients with acquired hemophilia]
- PMID: 25778884
- PMCID: PMC7342156
- DOI: 10.3760/cma.j.issn.0253-2727.2015.02.005
[A single-center clinical study of 22 patients with acquired hemophilia]
Abstract
Objective: To investigate the feature of underlying disorders, clinical symptoms, diagnosis and treatment strategies of patients with acquired hemophilia(AH).
Methods: The clinical data and laboratory tests results of 22 patients with AH from March 2010 to June 2014 were retrospectively analyzed.
Results: A total of 22 patients with AH were enrolled in our study, including 20 patients diagnosed as acquired hemophilia A (AHA) and 2 as acquired hemophilia B (AHB). Among the AHA patients, there were 10 males and 10 females with the median age of 37.5 (range, 2-95) years old. The median activity of FVIII (FVIII:C) of the 20 AHA patients was 1.9% (0.5%-39.0%). Soft tissue hematoma (80.0%) and subcutaneous bleeding (75.0%) were the most common clinical symptoms. Two male children were diagnosed as AHB (age 1 and 3 years old, respectively) with mild bleeding symptoms, and the activities of FIX (FIX:C) were 5.0% and 16.0%, respectively. In addition, an underlying disorder was found in 7 patients (31.8%). In laboratory testing, all patients had prolonged APTT, normal PT, decreased FVIII:C or FIX:C, positive antibody screening test or antibody titer (2-32 BU), and negative for lupus anticoagulant and anticardiolipin antibody. Nineteen out of 20 patients were treated with blood products to stop acute bleeding episodes. Corticosteroid alone was applied to 7 patients, corticosteroid combined with other immunosuppressive agents to 11 patients, rituximab to 3 patients. Nineteen patients responded well to hemostatic treatment, except 1 patient who died of fatal bleeding. The FVIII:C of 8 patients increased to a normal level with the median time of 42.5(21-145) days. After treatment, the activity of FIX:C of the 2 AHB patients achieved 35% and 24% in 48 and 60 days, respectively.
Conclusion: Acquired hemophilia is not an uncommon disease in clinical practices, which can occur in people of all ages. AH is a bleeding disorder with heterogeneous characteristics. Compared with adult, the clinical symptoms of children patients were mild, which lead to underdiagnosis.
目的: 探讨获得性血友病的病因、临床表现、临床诊断与治疗。
方法: 对2010年3月至2014年6月诊断的22例获得性血友病患者的临床资料进行回顾性分析。
结果: 22例患者中,获得性血友病A(AHA)20例(90.9%),获得性血友病B(AHB)2例(9.1%)。AHA患者中,男、女各10例,中位年龄37.5 (2~95)岁,中位凝血因子Ⅷ活性(FⅧ∶C)为1.9%(0.5%~39.0%),以肌肉软组织血肿(80.0%)、皮肤瘀斑(75.0%)为主要临床表现;2例AHB患者均为男性儿童(1、3岁各1例),临床症状轻微,凝血因子Ⅸ活性(FⅨ∶C)分别为5.0%、16.0%。22例患者中,7例(31.8%)存在相关病因。所有患者均APTT延长,PT正常,APTT纠正试验不能纠正或检出抑制物(滴度值2~32 BU),狼疮抗凝物及抗心磷脂抗体阴性。19例患者接受血制品止血治疗,7例患者单独使用肾上腺糖皮质激素清除抑制物,11例患者接受肾上腺糖皮质激素联合其他免疫抑制剂清除抑制物,3例患者接受利妥昔单抗治疗。20例AHA患者中19例(95.0%)急性出血控制,8例(40.0%)患者抑制物消失且FⅧ∶C>50%[中位治疗时间42.5(21~145)d],因出血死亡1例。2例AHB患者分别在治疗48、60 d后FⅨ∶C达到35%、24%。
结论: 获得性血友病并非罕见,可见于各年龄段,临床表现异质性高,儿童患者症状较轻。
Similar articles
-
Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia.Semin Thromb Hemost. 2009 Nov;35(8):769-77. doi: 10.1055/s-0029-1245109. Epub 2010 Feb 18. Semin Thromb Hemost. 2009. PMID: 20169513 Review.
-
Inhibitor eradication and bleeding management of acquired hemophilia A: a single center experience in China.Hematology. 2019 Dec;24(1):631-636. doi: 10.1080/16078454.2019.1663028. Hematology. 2019. PMID: 31514689
-
Clinical characteristics and outcomes of acquired hemophilia A: experience at a single center in Japan.Int J Hematol. 2017 Jul;106(1):82-89. doi: 10.1007/s12185-017-2210-8. Epub 2017 Mar 15. Int J Hematol. 2017. PMID: 28299631
-
Emicizumab for the treatment of acquired hemophilia A.Blood. 2021 Jan 21;137(3):410-419. doi: 10.1182/blood.2020006315. Blood. 2021. PMID: 32766881
-
Systemic lupus erythematosus with acquired hemophilia A: A case report and literature review.Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 May 28;48(5):789-794. doi: 10.11817/j.issn.1672-7347.2023.220440. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 37539582 Free PMC article. Review. Chinese, English.
Cited by
-
Rituximab for eradicating inhibitors in people with acquired haemophilia A.Cochrane Database Syst Rev. 2016 Jul 8;7(7):CD011907. doi: 10.1002/14651858.CD011907.pub2. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2021 Aug 23;8:CD011907. doi: 10.1002/14651858.CD011907.pub3. PMID: 27387850 Free PMC article. Updated.
-
A single-center study of patients with rare isolated acquired clotting factor deficiencies other than acquired hemophilia A.Res Pract Thromb Haemost. 2024 Aug 23;8(6):102554. doi: 10.1016/j.rpth.2024.102554. eCollection 2024 Aug. Res Pract Thromb Haemost. 2024. PMID: 39346578 Free PMC article.
-
Rituximab for eradicating inhibitors in people with acquired haemophilia A.Cochrane Database Syst Rev. 2021 Aug 23;8(8):CD011907. doi: 10.1002/14651858.CD011907.pub3. Cochrane Database Syst Rev. 2021. PMID: 34423414 Free PMC article.
References
-
- Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors[J] Br J Haematol. 2003;121(1):21–35. - PubMed
-
- Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII[J] Thromb Haemost. 1981;45(3):200–203. - PubMed
-
- Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation[J] Blood. 2007;109(5):1870–1877. - PubMed
-
- Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)[J] J Thromb Haemost. 2012;10(4):622–631. - PubMed
-
- 中华医学会血液学分会血栓与止血学组, 中国血友病协作组. 获得性血友病A诊断与治疗中国专家共识[J] 中华血液学杂志. 2014;35(6):575–576. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical